Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04743-6
As presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting, in a non-prespecified pooled analysis of two trials, amsokigene autoleucel, an autologous tumor-infiltrating lymphocyte therapy engineered to eliminate the need for IL-2, was successfully manufactured and well tolerated and showed a preliminary clinical efficacy signal in patients with immune checkpoint inhibitor-refractory melanoma.
